Interesting Case Study on Quality by Design for Vaccines
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
A case study issued in 2009 already concentrated on the application of Quality by Design for monoclonal antibodies. Now suggestions have been collected for a case study for vaccines. Five companies - GSK, Medimmune, Merck, Pfizer und Sanofi Pasteur - worked together in this Vaccine Working Group (VWG).
The VWG's goal was to find out whether and how QbD can be applied in the development and manufacture of vaccines.
The document from April 2012 comprises 383 pages!
A particularity with regard to vaccines is that most of these products are given prophylactically to healthy individuals.
A possible benefit mentioned is that a QbD approach also questions traditional proceedings in the development of vaccines. In any case, the application of QbD results in a better understanding of products and processes. It is also easier to predict the impact on future process changes.
Find further information in the PDA Case Study "A-VAX: Applying Quality by Design to Vaccines" (Size: 8.6 MB!).
Author:
Dr. Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development